Vinorelbine is marketed as NAVELBINE, a vinca alkaloid antineoplastic agent indicated for first-line treatment of locally advanced or metastatic non-small cell lung cancer, either with cisplatin or as single-agent therapy. U.S. initial approval was in 1994.
Ten-year follow-up of the phase 3 ESPATUE trial found similar overall and progression-free survival with chemoradiotherapy boost or surgery in resectable advanced NSCLC after induction therapy.
Multiple phase 3 breast cancer trials reported significant findings in early 2026, including positive results for novel therapies across different subtypes. Key data includes progression-free survival benefits for palbociclib in HR-positive, HER2-positive advanced breast cancer and investigations of antibody-drug conjugates and combination therapies. Full trial findings are expected to be presented at upcoming medical meetings.
A study published in Science sequenced cancer-related genes in 493 cat tumor samples across 13 cancer types, revealing striking genetic similarities with human cancers and opening possibilities for shared treatments.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07461454 |
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07420439 |
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT07021989 |
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07007559 |
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer |
RECRUITING | PHASE2 |
| NCT06908993 |
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated |
RECRUITING | PHASE3 |
| NCT06908304 |
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC |
RECRUITING | PHASE3 |
| NCT06857747 |
Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer. |
NOT_YET_RECRUITING | NA |
| NCT06692491 |
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS |
NOT_YET_RECRUITING | PHASE2 |
| NCT06632327 |
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer |
RECRUITING | PHASE3 |
| NCT06576635 |
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients |
RECRUITING | NA |
